Project Grant K99AI184675
- This $420,553 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop a single-cell technique that will measure the translation rate and transcriptome of thousands of individual bacterial cells, with a focus on understanding antibiotic tolerance in Staphylococcus aureus during chronic infections. The research will explore the heterogeneity in...
- This Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $188,916 award supports research by Brigham & Women's Hospital Inc. to investigate how the bacterium Staphylococcus aureus, a leading infectious cause of death globally, is able to evade the immune system and persist during bloodstream infections. The research aims to determine how noncytotoxic (non-toxic)...
- This $2,976,652 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), aims to explore how polyamines impact methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes, two dangerous human skin pathogens. The research will investigate how these pathogens develop resistance to polyamines, which are highly toxic to them, and seek to develop novel synthetic...
- This federal Project Grant award, totaling $404,108, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to identify the key genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) to form antibiotic persister cells, which can survive prolonged exposure to lethal antibiotics. The research aims to apply genetic and proteomic approaches to...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $402,284 to the University of North Carolina at Charlotte (UNC Charlotte) from August 18, 2025 to July 31, 2027. The goal of the project is to augment the host innate immune response against staphylococcal osteomyelitis, a severe bone infection caused by Staphylococcus aureus, through the use of antimicrobial nucleic...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $189,558 to Duke University to identify genomic determinants of antibiotic treatment failure in Staphylococcus aureus bacteremia (SAB). The primary objectives are to: 1) Use a murine in-vivo evolution model to identify bacterial genotypes associated with SAB treatment failure, and 2) Conduct a genome-wide...
- The University of South Florida (USF) received a $470,953 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant funding supports research to determine the role and regulation of the regulatory RNA SSR42 in virulence factor regulation in Staphylococcus aureus (S. aureus). The research aims to characterize how SSR42 impacts S. aureus virulence, including effects on hemolytic...
- The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $421,067 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on determining how neutrophil activities contribute to antibiotic treatment failure. The project aims to dissect the role of neutrophil extracellular traps (NETs) in promoting antibiotic tolerance in Staphylococcus aureus infections, evaluate...
- This $226,253 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how the host protein ADAM10 modulates the interactions between neutrophils and the endothelium during Staphylococcus aureus infection. The project aims to generate a spatiotemporal analysis of these key cellular and molecular interactions in the early stages of infection, leveraging...
- The National Institute of Allergy and Infectious Diseases awarded a $410,000 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Trustees of Princeton University to conduct research examining the influence of chromosome copy number on Pseudomonas aeruginosa persisters to fluoroquinolones. The project, with a performance period from Apr 15, 2025 to Mar 31, 2027, will investigate how the number of chromosome copies in individual P. aeruginosa...
This Project Grant award of $115,123 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to reveal strategies for eradicating antibiotic-tolerant Staphylococcus aureus persister cells. The research aims to identify the host cells harboring intracellular S. aureus reservoirs and characterize the host and bacterial transcriptomes using single-cell approaches. Additionally, the project establishes a high-throughput screening platform to identify modulators of intracellular S. aureus energy levels, a key factor underlying persister cell antibiotic tolerance. The project period runs from August 2025 to July 2027 and is being conducted by the University of North Carolina at Chapel Hill.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $115.1k | 8/20/25 |